Tag: LimFlow

Dr. Pedro Martinez-Clark, Founder of Amavita Heart and Vascular™, Partners with LimFlow®, an FDA Approved System for Chronic Limb-Threatening Ischemia Patients

MIAMI, Nov. 7, 2024 /PRNewswire/ — Pedro Martinez-Clark, MD, FACC, a renowned Harvard-trained cardiologist and founder of Amavita Heart and Vascular™, has joined forces with LimFlow® to offer an innovative solution for patients suffering from chronic limb-threatening ischemia (CLTI)….

FDA Approves LimFlow System in Patients With Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revascularization Options

PARIS & SAN JOSE, Calif.–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration […]

Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation

PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), […]

Late-breaking Data From PROMISE I Study On LimFlow System Confirm Excellent Sustained Outcomes In Patients With No-option Chronic Limb-threatening Ischemia

Limb salvage in 77 percent of patients at 2 years with “no-option” for revascularization via traditional techniques 24-Month Results Presented Wednesday at VIVA 2021 Conference SAN JOSE, Calif. and LAS VEGAS, Oct. 7, 2021 /PRNewswire/ — LimFlow SA, the pioneer in the development of minimally-invasive […]

LimFlow System Demonstrates Excellent Sustained Amputation-free Survival and Wound Healing at One Year in PROMISE I U.S. Study

Twelve-Month Results Presented Today in Late-Breaking Trials Session at Vascular Interventional Advances (VIVA) Conference PARIS–(BUSINESS WIRE)–LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease […]

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-Free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

Multicenter, International ALPS Registry Outcomes Just Published in Journal of Endovascular Therapy PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), […]